Noriaki Hirayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noriaki Hirayama has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Hideto Isogai
Department of Basic and Molecular Medicine, Tokai University School of Medicine
4 shared publicationsRumiko Sakurai
Yamakawa Chemical Industry Co. Ltd
3 shared publicationsHiroki Shirai
Molecular Medicine Research Laboratories , Drug Discovery Research , Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 , Japan
2 shared publicationsHiroko Miyadera
Department of Human Genetics, Graduate School of Medicine, The University of Tokyo
2 shared publicationsJunichi Goto
Science and Technology Systems Division, Computational Science Department, Ryoka Systems Inc., 1-28-38 Shinkawa, Chuo-ku, Tokyo 104-0033, Japan
2 shared publicationsMasato Kobori
Molecular Medicine Research Laboratories , Drug Discovery Research , Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 , Japan
2 shared publications
Latest Publications
- 1 August 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (8) , 1659-1662.e6
Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients
- 1 August 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (8) , 1659-1662.e6
Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients
- Open Access
- 2 March 2020
- Published by Chem-Bio Informatics Society in Chem-Bio Informatics Journal
- Vol. 20, 1-4
HLABAP: HLA Class I-Binding Antigenic Peptide Predictor
HLA (Human Leucocyte Antigen) class I molecules present a variable but limited repertoire of antigenic peptides for T-cell recognition. Identification of specific antigenic peptides is essential for the development of immunotherapy. High polymorphism of HLA genes and a large number of possible peptides to be evaluated, however, have made the identification by experiments costly and time-consuming. Computational methods have been proposed to address this problem. In cases where plenty number of binding affinity data of peptides are available, various QSAR and machine learning approaches efficiently evaluate the affinity of test peptides, while in the cases where just a little data are available, structure-based approaches like elaborate docking have been proposed. We have developed a software named HLABAP that is designed to predict the binding affinities for a set of peptides against a particular HLA class I allele. By the combination of homology modeling for posing instead of docking and geometry optimization of the complex structures between the HLA molecule and peptides, HLABAP well predicts the binding affinities for the peptides. The results have shown that HLABAP should be applicable to identify possible antigenic peptides against a particular allele of HLA class I prior to the experiments far efficiently than the ordinary docking methods.
- 2 March 2020
- Published by Chem-Bio Informatics Society in Chem-Bio Informatics Journal
- Vol. 20, 1-4
Open AccessHLABAP: HLA Class I-Binding Antigenic Peptide Predictor
HLA (Human Leucocyte Antigen) class I molecules present a variable but limited repertoire of antigenic peptides for T-cell recognition. Identification of specific antigenic peptides is essential for the development of immunotherapy. High polymorphism of HLA genes and a large number of possible peptides to be evaluated, however, have made the identification by experiments costly and time-consuming. Computational methods have been proposed to address this problem. In cases where plenty number of binding affinity data of peptides are available, various QSAR and machine learning approaches efficiently evaluate the affinity of test peptides, while in the cases where just a little data are available, structure-based approaches like elaborate docking have been proposed. We have developed a software named HLABAP that is designed to predict the binding affinities for a set of peptides against a particular HLA class I allele. By the combination of homology modeling for posing instead of docking and geometry optimization of the complex structures between the HLA molecule and peptides, HLABAP well predicts the binding affinities for the peptides. The results have shown that HLABAP should be applicable to identify possible antigenic peptides against a particular allele of HLA class I prior to the experiments far efficiently than the ordinary docking methods.
- Open Access
- 7 February 2019
- Published by Chem-Bio Informatics Society in Chem-Bio Informatics Journal
- Vol. 19, 1-4
In silico analysis of interactions of flucloxacillin and its metabolites with HLA-B*57:01
An antibiotic flucloxacillin (FX) which is widely used for the treatment of staphylococcal infection, is known to cause liver injury. A genome-wide association study has shown that FX induced idiosyncratic drug toxicity (IDT) is associated with HLA-B*57:01. FX is processed in the human body to produce several metabolites. Molecular interactions of FX or its metabolites with HLA-B*57:01 should play a crucial role in the occurrence of the adverse drug reaction. In this study, we have undertaken docking simulations of interactions of FX and its metabolites with HLA-B*57:01 to understand molecular mechanisms leading to the onset of IDT.
- 7 February 2019
- Published by Chem-Bio Informatics Society in Chem-Bio Informatics Journal
- Vol. 19, 1-4
Open AccessIn silico analysis of interactions of flucloxacillin and its metabolites with HLA-B*57:01
An antibiotic flucloxacillin (FX) which is widely used for the treatment of staphylococcal infection, is known to cause liver injury. A genome-wide association study has shown that FX induced idiosyncratic drug toxicity (IDT) is associated with HLA-B*57:01. FX is processed in the human body to produce several metabolites. Molecular interactions of FX or its metabolites with HLA-B*57:01 should play a crucial role in the occurrence of the adverse drug reaction. In this study, we have undertaken docking simulations of interactions of FX and its metabolites with HLA-B*57:01 to understand molecular mechanisms leading to the onset of IDT.
- Open Access
- 4 June 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (6) , 1660
Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex
Human leukocyte antigen (HLA)-DRB1*01:01 has been shown to be involved in nevirapine-induced hepatic hypersensitivity reactions. In the present study, in silico docking simulations and molecular dynamics simulations were performed to predict the interaction mode of nevirapine with the peptide binding groove of HLA-DRB1*01:01 and its possible effect on the position and orientation of the ligand peptide derived from hemagglutinin (HA). In silico analyses suggested that nevirapine interacts with HLA-DRB1*01:01 around the P4 pocket within the peptide binding groove and the HA peptide stably binds on top of nevirapine at the groove. The analyses also showed that binding of nevirapine at the groove will significantly change the inter-helical distances of the groove. An in vitro competitive assay showed that nevirapine (1000 μM) increases the binding of the HA peptide to HLA-DRB1*01:01 in an allele-specific manner. These results indicate that nevirapine might interact directly with the P4 pocket and modifies its structure, which could change the orientation of loaded peptides and the conformation of HLA-DRB1*01:01; these changes could be distinctively recognized by T-cell receptors. Through this molecular mechanism, nevirapine might stimulate the immune system, resulting in hepatic hypersensitivity reactions.
- 4 June 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (6) , 1660
Open AccessInteraction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex
Human leukocyte antigen (HLA)-DRB1*01:01 has been shown to be involved in nevirapine-induced hepatic hypersensitivity reactions. In the present study, in silico docking simulations and molecular dynamics simulations were performed to predict the interaction mode of nevirapine with the peptide binding groove of HLA-DRB1*01:01 and its possible effect on the position and orientation of the ligand peptide derived from hemagglutinin (HA). In silico analyses suggested that nevirapine interacts with HLA-DRB1*01:01 around the P4 pocket within the peptide binding groove and the HA peptide stably binds on top of nevirapine at the groove. The analyses also showed that binding of nevirapine at the groove will significantly change the inter-helical distances of the groove. An in vitro competitive assay showed that nevirapine (1000 μM) increases the binding of the HA peptide to HLA-DRB1*01:01 in an allele-specific manner. These results indicate that nevirapine might interact directly with the P4 pocket and modifies its structure, which could change the orientation of loaded peptides and the conformation of HLA-DRB1*01:01; these changes could be distinctively recognized by T-cell receptors. Through this molecular mechanism, nevirapine might stimulate the immune system, resulting in hepatic hypersensitivity reactions.
- 1 June 2016
- Published by Chem-Bio Informatics Society in Chem-Bio Informatics Journal
- Vol. 16, 5-8
In silico Analysis of Interactions between HLA-A*31:01 and carbamazepine-related Compounds
- 1 June 2016
- Published by Chem-Bio Informatics Society in Chem-Bio Informatics Journal
- Vol. 16, 5-8
In silico Analysis of Interactions between HLA-A*31:01 and carbamazepine-related Compounds
- Open Access
- 25 October 2015
- Published by Chem-Bio Informatics Society in Chem-Bio Informatics Journal
- Vol. 15, 1-4
Insight into the Intermolecular Recognition Mechanism between HLA-A*24:02 and Antitumor Peptides against Breast Cancer
- 25 October 2015
- Published by Chem-Bio Informatics Society in Chem-Bio Informatics Journal
- Vol. 15, 1-4
Open AccessInsight into the Intermolecular Recognition Mechanism between HLA-A*24:02 and Antitumor Peptides against Breast Cancer
- Open Access
- 27 November 2013
- Published by Wiley in International Journal of Medicinal Chemistry
- Vol. 2013, 1-6
HLA-Modeler: Automated Homology Modeling of Human Leukocyte Antigens
The three-dimensional (3D) structures of human leukocyte antigen (HLA) molecules are indispensable for the studies on the functions at molecular level. We have developed a homology modeling system named HLA-modeler specialized in the HLA molecules. Segment matching algorithm is employed for modeling and the optimization of the model is carried out by use of the PFROSST force field considering the implicit solvent model. In order to efficiently construct the homology models, HLA-modeler uses a local database of the 3D structures of HLA molecules. The structure of the antigenic peptide-binding site is important for the function and the 3D structure is highly conserved between various alleles. HLA-modeler optimizes the use of this structural motif. The leave-one-out cross-validation using the crystal structures of class I and class II HLA molecules has demonstrated that the rmsds of nonhydrogen atoms of the sites between homology models and crystal structures are less than 1.0 Å in most cases. The results have indicated that the 3D structures of the antigenic peptide-binding sites can be reproduced by HLA-modeler at the level almost corresponding to the crystal structures.
- 27 November 2013
- Published by Wiley in International Journal of Medicinal Chemistry
- Vol. 2013, 1-6
Open AccessHLA-Modeler: Automated Homology Modeling of Human Leukocyte Antigens
The three-dimensional (3D) structures of human leukocyte antigen (HLA) molecules are indispensable for the studies on the functions at molecular level. We have developed a homology modeling system named HLA-modeler specialized in the HLA molecules. Segment matching algorithm is employed for modeling and the optimization of the model is carried out by use of the PFROSST force field considering the implicit solvent model. In order to efficiently construct the homology models, HLA-modeler uses a local database of the 3D structures of HLA molecules. The structure of the antigenic peptide-binding site is important for the function and the 3D structure is highly conserved between various alleles. HLA-modeler optimizes the use of this structural motif. The leave-one-out cross-validation using the crystal structures of class I and class II HLA molecules has demonstrated that the rmsds of nonhydrogen atoms of the sites between homology models and crystal structures are less than 1.0 Å in most cases. The results have indicated that the 3D structures of the antigenic peptide-binding sites can be reproduced by HLA-modeler at the level almost corresponding to the crystal structures.
- Open Access
- 23 October 2013
- Published by Wiley in Journal of Crystallography
- Vol. 2013, 1-3
Crystal Structure of Apraclonidine Hydrochloride
Apraclonidine is used for the treatment of postsurgical elevated intraocular pressure. The crystal structure of its hydrochloride, C9H10Cl2N4·HCl, was determined by X-ray analysis. The crystal belongs to space group with the cell dimensions , , Å, and °. The final (all reflections) value is 0.053. Apraclonidine has a more twisted structure than its related drug of clonidine. The nitrogen atom bridging the two rings is protonated.- 23 October 2013
- Published by Wiley in Journal of Crystallography
- Vol. 2013, 1-3
Open AccessCrystal Structure of Apraclonidine Hydrochloride
Apraclonidine is used for the treatment of postsurgical elevated intraocular pressure. The crystal structure of its hydrochloride, C9H10Cl2N4·HCl, was determined by X-ray analysis. The crystal belongs to space group with the cell dimensions , , Å, and °. The final (all reflections) value is 0.053. Apraclonidine has a more twisted structure than its related drug of clonidine. The nitrogen atom bridging the two rings is protonated. - Open Access
- 12 October 2013
- Published by Wiley in Journal of Toxicology
- Vol. 2013, 1-6
In SilicoRisk Assessment of HLA-A*02:06-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Caused by Cold Medicine Ingredients
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug hypersensitivities with high mortality. Typical over-the-counter drugs of cold medicines are suggested to be causative. As multiple ingredients are generally contained in cold medicines, it is of particular interest to investigate which ingredients are responsible for SJS/TEN. However, experimental examination of causal relationships between SJS/TEN and a particular drug molecule is not straightforward. Significant association between HLA-A*02:06 and SJS/TEN with severe ocular surface complications has been observed in the Japanese. In the present study, we have undertakenin silicodocking simulations between various ingredients contained in cold medicines available in Japan and the HLA-A*02:06 molecule. We use the composite risk index (CRI) that is the absolute value of the binding affinity multiplied by the daily dose to assess the potential risk of the adverse reactions. The drugs which have been recognized as causative drugs of SJS/TEN in Japan have revealed relatively high CRI, and the association between SJS/TEN and HLA-A*02:06 has been qualitatively verified. The results have also shown that some drugs whose links to SJS/TEN have not been clinically recognized in Japan show the high CRI and suggested that attention should be paid to their adverse drug reactions.
- 12 October 2013
- Published by Wiley in Journal of Toxicology
- Vol. 2013, 1-6
Open AccessIn SilicoRisk Assessment of HLA-A*02:06-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Caused by Cold Medicine Ingredients
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug hypersensitivities with high mortality. Typical over-the-counter drugs of cold medicines are suggested to be causative. As multiple ingredients are generally contained in cold medicines, it is of particular interest to investigate which ingredients are responsible for SJS/TEN. However, experimental examination of causal relationships between SJS/TEN and a particular drug molecule is not straightforward. Significant association between HLA-A*02:06 and SJS/TEN with severe ocular surface complications has been observed in the Japanese. In the present study, we have undertakenin silicodocking simulations between various ingredients contained in cold medicines available in Japan and the HLA-A*02:06 molecule. We use the composite risk index (CRI) that is the absolute value of the binding affinity multiplied by the daily dose to assess the potential risk of the adverse reactions. The drugs which have been recognized as causative drugs of SJS/TEN in Japan have revealed relatively high CRI, and the association between SJS/TEN and HLA-A*02:06 has been qualitatively verified. The results have also shown that some drugs whose links to SJS/TEN have not been clinically recognized in Japan show the high CRI and suggested that attention should be paid to their adverse drug reactions.
- Open Access
- 9 April 2013
- Published by Wiley in International Journal of Medicinal Chemistry
- Vol. 2013, 1-4
A Possible Molecular Mechanism of Immunomodulatory Activity of Bilirubin
Bilirubin is an endogenous product of heme degradation in mammals. Bilirubin has long been considered as a cytotoxic waste product that needs to be excreted. However, increasing evidence suggests that bilirubin possesses multiple biological activities. In particular, recent studies have shown that bilirubin should be a protective factor for several autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. Since these autoimmune diseases are closely associated with specific types of human leukocyte antigens (HLAs), we have hypothesized that bilirubin might bind to the antigenic peptide-binding groove of the HLA molecules and exert its immunosuppressive actions. In order to evaluate the hypothesis, theoretical docking studies between bilirubin and the relevant HLA molecules have been undertaken. The in silico studies have clearly shown that bilirubin may bind to the antigenic peptide-binding groove of the HLA molecules relevant to the autoimmune diseases with significant affinity. The bound bilirubin may block the binding of antigenic peptides to be presented to T cell receptors and lead to suppression of the autoimmune responses. Based on this hypothesis new drug discovery research for autoimmune diseases will be conducted.
- 9 April 2013
- Published by Wiley in International Journal of Medicinal Chemistry
- Vol. 2013, 1-4
Open AccessA Possible Molecular Mechanism of Immunomodulatory Activity of Bilirubin
Bilirubin is an endogenous product of heme degradation in mammals. Bilirubin has long been considered as a cytotoxic waste product that needs to be excreted. However, increasing evidence suggests that bilirubin possesses multiple biological activities. In particular, recent studies have shown that bilirubin should be a protective factor for several autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. Since these autoimmune diseases are closely associated with specific types of human leukocyte antigens (HLAs), we have hypothesized that bilirubin might bind to the antigenic peptide-binding groove of the HLA molecules and exert its immunosuppressive actions. In order to evaluate the hypothesis, theoretical docking studies between bilirubin and the relevant HLA molecules have been undertaken. The in silico studies have clearly shown that bilirubin may bind to the antigenic peptide-binding groove of the HLA molecules relevant to the autoimmune diseases with significant affinity. The bound bilirubin may block the binding of antigenic peptides to be presented to T cell receptors and lead to suppression of the autoimmune responses. Based on this hypothesis new drug discovery research for autoimmune diseases will be conducted.